Based on our experience and evidence-based management of AA amyloidosis, nephroprotective strategies, including the use of renin-angiotensin system inhibitors such as ACE inhibitors or ARBs and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are recommended to reduce proteinuria and slow renal decline. Here, SLC5A2 is linked to AA amyloidosis.